Literature DB >> 24046000

Signaling between tumor cells and the host bone marrow microenvironment.

Natasa Kovacic1, Peter I Croucher, Michelle M McDonald.   

Abstract

Tumor cells with high skeletal homing affinity express numerous cell surface receptors that bind ligands produced in bone. Upon arrival, these cells survive in the host environment, encompassed in close proximity to bone marrow cells. Interactions between tumor cells and cells of the host microenvironment are essential to not only tumor cell survival but also their activation and proliferation into environment-modifying tumors. Through the production of RANKL, PTHrP, cytokines, and integrins, activated tumor cells stimulate osteoclastogenesis, enhance bone resorption, and subsequently release matrix-bound proteins that further promote tumor growth and bone resorption. In addition, alterations in the TGF-β/BMP and Wnt signaling pathways via tumor cell growth can either stimulate or suppress osteoblastic bone formation and function, leading to sclerotic or lytic bone disease, respectively. Hence, the presence of tumor cells in bone dysregulates bone remodeling, dramatically impairing skeletal integrity. Furthermore, through complex mechanisms, cells of the immune system interact with tumor cells to further impact bone remodeling. Lastly, with alterations in bone cell activity, the environment is permissive to promoting tumor growth further, suggesting an interdependence between tumor cells and bone cells in metastatic bone disease and multiple myeloma.

Entities:  

Mesh:

Year:  2013        PMID: 24046000     DOI: 10.1007/s00223-013-9794-7

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  8 in total

Review 1.  Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast.

Authors:  Michaela R Reagan; Lucy Liaw; Clifford J Rosen; Irene M Ghobrial
Journal:  Bone       Date:  2015-02-26       Impact factor: 4.398

Review 2.  Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets.

Authors:  Nadia Rucci; Patrizia Sanità; Simona Delle Monache; Edoardo Alesse; Adriano Angelucci
Journal:  World J Clin Oncol       Date:  2014-08-10

Review 3.  Denosumab: an Emerging Therapy in Pediatric Bone Disorders.

Authors:  Alison M Boyce
Journal:  Curr Osteoporos Rep       Date:  2017-08       Impact factor: 5.096

Review 4.  Navigating the bone marrow niche: translational insights and cancer-driven dysfunction.

Authors:  Michaela R Reagan; Clifford J Rosen
Journal:  Nat Rev Rheumatol       Date:  2015-11-26       Impact factor: 20.543

Review 5.  Multiple myeloma in the marrow: pathogenesis and treatments.

Authors:  Heather Fairfield; Carolyne Falank; Lindsey Avery; Michaela R Reagan
Journal:  Ann N Y Acad Sci       Date:  2016-01       Impact factor: 5.691

6.  Intercellular signaling between ameloblastoma and osteoblasts.

Authors:  Elissa Chairani; Takao Fuchigami; Hirofumi Koyama; Yusuke Ono; Mikio Iijima; Michiko Kishida; Toshiro Kibe; Norifumi Nakamura; Shosei Kishida
Journal:  Biochem Biophys Rep       Date:  2022-02-18

7.  Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression.

Authors:  Zhiqiang Liu; Jingda Xu; Haiyan Li; Yuhuan Zheng; Jin He; Huan Liu; Yuping Zhong; Yong Lu; Bangxing Hong; Mingjun Zhang; Pei Lin; Juan Du; Jian Hou; Jianfei Qian; Larry W Kwak; Qing Yi; Jing Yang
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

8.  Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23.

Authors:  Patrick L Mulcrone; Shanique K E Edwards; Daniela N Petrusca; Laura S Haneline; Jesús Delgado-Calle; G David Roodman
Journal:  Sci Rep       Date:  2020-10-14       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.